Magnetized wire could be used to detect cancer in people
Scientists at Stanford used a magnetic wire to capture free-floating tumor cells in the blood, a technique that soon could be used in humans to yield an earlier cancer diagnosis.07/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 18, 2018 Category: Urology & Nephrology Source Type: news
Researchers suggest new treatment for rare inherited cancers
While studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA.07/18/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 18, 2018 Category: Urology & Nephrology Source Type: news
BMS ’ Opdivo/Yervoy combo cleared for kidney cancer
Approval was based on data from the Phase III CheckMate -214 clinical trial, in which the Opdivo (nivolumab) + Yervoy (ipilimumab) combination showed “a significant and unprecedented increase in overall survival (OS) in this patient population compared to a current standard of care, sunitinib,” according to BMS.07/16/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 16, 2018 Category: Urology & Nephrology Source Type: news
Patients with early kidney cancer see significant benefits with robotic partial nephrectomy
A comprehensive study by the Keck School of Medicine of USC has found that robotic partial nephrectomy offers significantly better patient outcomes.07/11/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 13, 2018 Category: Urology & Nephrology Source Type: news
A Call for Better Screening for Hereditary Renal Cell Carcinoma
It may be time to adopt a broader approach to tumor and matched normal sequencing in patients with advanced renal cell carcinoma (RCC), according to a large new study.07/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 13, 2018 Category: Urology & Nephrology Source Type: news
Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer mimic
Anastomosing hemangioma (ah) is a rare subtype of primary vascular tumour that can, clinically and radiologically, present similarly to malignant renal tumours such as renal cell carcinoma (rcc) and angiosarcoma.07/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 12, 2018 Category: Urology & Nephrology Source Type: news
nts with early kidney cancer see significant benefits with robotic partial nephrectomy
A comprehensive study by the Keck School of Medicine of USC has found that robotic partial nephrectomy offers significantly better patient outcomes.07/11/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 11, 2018 Category: Urology & Nephrology Source Type: news
Targeting tumor-associated acidity in cancer immunotherapy
Checkpoint inhibitors, such as cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programmed cell death-1 (PD-1) monoclonal antibodies have changed profoundly the treatment of melanoma, renal cell carcinoma, non-small cell lung cancer, Hodgkin lymphoma, and bladder cancer. Currently, they are tested in various tumor entities as monotherapy or in combination with chemotherapies or targeted therapies. However, only a subgroup of patients benefit from checkpoint blockade (combinations).07/11/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 11, 2018 Category: Urology & Nephrology Source Type: news
GSK kidney cancer drug approved in U.S.
GlaxoSmithKline's Votrient has been approved in the U.S. by the FDA to treat the most common form of kidney cancer.07/10/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 10, 2018 Category: Urology & Nephrology Source Type: news
This is how a 9-year-old celebrates being cancer free
Nine-year-old JaKiah Collins had a big doctor's appointment ahead of her. She was used to coming to the hospital; she'd been in and out of hospitals for years. But this appointment was a big milestone.07/10/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 10, 2018 Category: Urology & Nephrology Source Type: news
Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma
In the CheckMate 214 trial, Motzer et al found higher overall survival among intermediate- and poor-risk patients with previously untreated metastatic renal-cell carcinoma who received nivolumab plus ipilimumab than among those who received sunitinib07/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 10, 2018 Category: Urology & Nephrology Source Type: news
Otago scientists' breakthrough in childhood kidney cancer
A world-first discovery by University of Otago scientists may change the way children suffering from a rare form of kidney cancer are treated.07/03/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 3, 2018 Category: Urology & Nephrology Source Type: news
Robotic surgery is no better than traditional surgery, study finds
Robotic-assisted procedures have now become ubiquitous in some kinds of surgeries. What once was seen as a technological marvel is commonplace in many hospitals.
But studies in recent years have shown robotic surgery performs no better than traditional surgery - even though it comes at a steeper cost to the overall health-care system.06/29/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 2, 2018 Category: Urology & Nephrology Source Type: news
Gender May Play a Role in Immunotherapy Efficacy, Further Studies Are Warranted
Immunotherapy continues to evolve as a treatment option for various cancers; however, men may see more benefit from it more than women, according to a study published in The Lancet Oncology.06/29/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 2, 2018 Category: Urology & Nephrology Source Type: news
The Secrets of Spontaneous Cancer Remission
Once in a rare while, we hear a story of someone given months or weeks to live who ends up surviving and defiantly thriving. Like the first person to run a four-minute mile, climb Mt. Everest, or walk on the moon, such individuals are living proof that the impossible is possible. Yet because their experience is so far outside the norm, these survivors have been labeled medical anomalies and set aside from the lens of research. That is, until Kelly Turner, PhD, came along. The author of Radical Remission: Surviving Cancer Against All Odds (HarperCollins, 2014), Turner has studied hundreds of spontaneous-remission cases to s...
Source: Kidney Cancer Association - July 2, 2018 Category: Urology & Nephrology Source Type: news
